Rani Therapeutics Appoints Lyn Baranowski to Board of Directors
Rani Therapeutics Holdings (Nasdaq: RANI) announced the appointment of Lyn Baranowski to its Board of Directors, effective November 12, 2021. Baranowski brings 18 years of experience in the biotechnology sector, having held key roles at Altavant Sciences, Melinta Therapeutics, and AstraZeneca. CEO Talat Imran emphasized her expertise in strategic partnerships and financial transactions, which will be pivotal as Rani progresses its oral biologics delivery technology, RaniPill. This innovation aims to transform patient care by replacing injections with oral alternatives.
- Appointment of Lyn Baranowski strengthens leadership with extensive biotech experience.
- Baranowski's background in strategic partnerships may drive growth for Rani.
- Focus on the RaniPill technology could enhance market position and patient outcomes.
- Transitioning leadership may create initial continuity challenges.
SAN JOSE, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics, today announced the appointment of Lyn Baranowski to its Board of Directors. Ms. Baranowski is a distinguished biotechnology executive with nearly two decades of experience.
“Lyn is a well-respected biotechnology executive whose deep experience includes a diverse set of product portfolios and therapeutic areas,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “Lyn’s track record in creating strategic partnerships and executing complex financial transactions involving preclinical to commercial stage assets will be invaluable as we continue to advance our technology and grow the company.”
Lyn Baranowski has 18 years’ experience building, directing and guiding biopharmaceutical companies. Currently, Ms. Baranowski serves as the Chief Operating Officer at Altavant Sciences, a clinical stage biopharmaceutical company focused on rare respiratory diseases. Prior to Altavant, Ms. Baranowski served as the Senior Vice President, Corporate Development and Strategy at Melinta Therapeutics, where she guided the company through significant milestones including the FDA’s approval of the company’s lead asset, a successful public listing, and an acquisition of a key business unit from the Medicines Company. Prior to Melinta, Ms. Baranowski was the Vice President, Commercial Development at Pearl Therapeutics where she was instrumental in the company’s acquisition by AstraZeneca. Earlier in her career, Ms. Baranowski was Vice President at Vatera Healthcare, a private equity / venture capital firm, and held a variety of roles in business development, marketing and policy with Novartis Pharmaceuticals.
“The RaniPill is a disruptive technology with the potential to revolutionize the way biologics are delivered, and I am thrilled to be involved with a company at the forefront of replacing painful injections with pain-free, oral alternatives,” said Lyn Baranowski. “I look forward to leveraging my experience guiding strategic transactions to help Rani achieve its goals as the company progresses its development pipeline into and eventually through the clinic.”
Ms. Baranowski received her BA in international studies from American University as well as an MBA from Harvard Business School.
About Rani Therapeutics
Rani Therapeutics is a clinical stage biotherapeutics company focused on the oral delivery of biologics, which we believe will have the potential to transform medicine and improve patient outcomes. The company has developed the RaniPill™ capsule, a novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using the RaniPill™ capsule.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, Rani’s advancement of its RaniPill™ capsule technology, the impact of its technology on medical treatment, Rani’s advancement of its preclinical and clinical programs, and Rani’s growth as a company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “may,” “look forward,” “progress,” “advance” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Rani’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Rani’s business in general, the impact of the COVID-19 pandemic, and the other risks described in Rani’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Rani undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
Source: Rani Therapeutics
FAQ
Who is Lyn Baranowski and what is her role at Rani Therapeutics?
What experience does Lyn Baranowski have in the biotech industry?
What is the RaniPill technology mentioned in the press release?
How might Lyn Baranowski's appointment affect Rani Therapeutics?
When was Lyn Baranowski appointed to the Board of Directors of Rani Therapeutics?
